Summit Rewind 2021

Publication Highlights

National Experts’ Perspectives: State of the Art Breast Cancer Treatment in 2021 An expert panel highlights treatment options for HER2-positive metastatic and triple-negative breast cancer. Page 4

Oncology Biosimilars: Educating the Oncology Health Care Team to Facilitate Implementation into Clinical Practice Barriers that come with implementing biosimilars into clinical practice and methods to overcome them. Page 4

New Updates in CAR-T Cellular Therapy A primer on Immuno-Effector Cell Therapies, including a look at CAR-T’s efficacy, adverse effects & future potential. Page 5

Drug Interactions for Oncology Management: Navigating IV & Oral Therapies Pharmacists must be mindful about potential DDIs and how they affect patients on oral oncolytics. Page 5

Evolving Treatment Strategies for Adjuvant & Metastatic Melanoma While melanoma is the fifth most common cancer, current therapies offer a high survival rate for many patients. Page 6

Exploring Strategies for Treating Solid Tumors with PARP Inhibitors How nuanced considerations of PARP inhibitors highlight the strategic role of healthcare practitioners in cancer therapy. Page 6

The Evolution of Telehealth Services The growth of telehealth services in the world of oncology and the challenges of implementing them in practice. Page 7

Consistent Clinical Standards & NCODA Resources for Medically Integrated Teams A look at the PQI, PQI in Action, TSK, Oral Chemotherapy Education (OCE) & IV Chemotherapy Education (IVE) initiatives. Page 7

Identifying and Overcoming Patient and Caregiver Fatigue Understanding the differences between burnout and compassion fatigue, and strategies on how to avoid them. Page 19

Addressing Disparities: Advancing Healthcare Equity A discussion regarding promotion of equity care and staffing within the current healthcare system in the US. Page 19

Understanding How Legislation & Policy Works for You, Your Patients & Practice How a monumental Supreme Court ruling helped wrest total market control from Pharmacy Benefit Managers. Page 20

New & Emerging Oral Oncolytics & the Role of the Oncology Team in Optimizing Outcomes An examination of the newly-approved drugs sotorasib, infigratinib, belzutifan and mobocertinib. Page 21

Exploring Advancements of Evidence-Based Testing and Treatment Strategies in CLL A detailed look at Chronic Lymphotic Leukemia, including current treatment options and financial challenges. Page 21

Improving Medication Adherence by Empowering Patients to Utilize Resources NCODA has created several innovative tools to help improve prescription adherence of patients taking oral and IV oncolytics. Page 22

NCODA’s New Medically Integrated Pharmacy Accreditation Program NCODA CoE MIP program is the preferred accreditation for Prime Therapeutics’ IntegratedRx™ Oncology Program. Page 22